Related references
Note: Only part of the references are listed.Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer
Emer O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding
Banibrata Sen et al.
CANCER RESEARCH (2009)
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Metabolism and disposition of dasatinib after oral administration to humans
Lisa J. Christopher et al.
DRUG METABOLISM AND DISPOSITION (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: Advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors
Syed M. Ahmed et al.
CURRENT CANCER DRUG TARGETS (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number
Marta Canel et al.
CLINICAL CANCER RESEARCH (2006)
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
FM Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants
NC duPont et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2005)
Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma
Y Ren et al.
ANNALS OF SURGERY (2005)
Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology
LD Giavedoni
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Role of Src expression and activation in human cancer
RB Irby et al.
ONCOGENE (2000)
An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis
H Ogawa et al.
CYTOKINE (2000)
Share Paper
